Creative Planning
KYMR icon

Creative Planning’s Kymera Therapeutics KYMR Stock Holding History

Creative Planning’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.35M Buy
28,246
+14,477
+105% +$1.15M ﹤0.01% 1774
2025
Q4 		$1.07M Buy
13,769
+8,742
+174% +$590K ﹤0.01% 2221
2025
Q3 		$285K Buy
+5,027
New +$227K ﹤0.01% 3186
2025
Q1 		– Sell
-487
Closed -$19.6K – 3610
2024
Q4 		$19.6K Buy
+487
New +$22K ﹤0.01% 3341

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Creative Planning's KYMR Position: Q1 2026 in Review

Creative Planning increased its Kymera Therapeutics (KYMR) stake by 105% in Q1 2026, buying an estimated $1.15M and bringing the position to 28,246 shares worth $2.35M. The position accounts for ﹤0.01% of the portfolio, ranked #1774.

Creative Planning first reported a position in KYMR in Q4 2024 and has held it in 4 quarters since. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Creative Planning held 28,246 shares of Kymera Therapeutics worth $2.35M as of Q1 2026.
  • Creative Planning bought 14,477 Kymera Therapeutics shares in Q1 2026, an estimated $1.15M.
  • Kymera Therapeutics made up ﹤0.01% of Creative Planning's portfolio in Q1 2026, its #1774 holding.
  • Creative Planning first reported a position in Kymera Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.